Klimik Journal最新文献

{"title":"Antiviral Treatment Results and Side Effects During Treatment in Chronic Hepatitis B Patients","authors":"Rukiyye Bulut, Esma Kepenek Kurt, B. Kandemir, I. Erayman, M. Bitirgen","doi":"10.36519/kd.2021.3672","DOIUrl":"https://doi.org/10.36519/kd.2021.3672","url":null,"abstract":"","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48082268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Bacterial Gastroenteritis Agents in Patients Who Admitted to Pediatric Clinic with Diarrhea","authors":"Muhammet Sukru Agralı, M. Doğan","doi":"10.36519/kd.2021.3683","DOIUrl":"https://doi.org/10.36519/kd.2021.3683","url":null,"abstract":"","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47174285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge Levels of Needlestick and Sharps Injuries about Nursing and Midwifery Students","authors":"Hayriye Öztürk Mentese, A. Karaca","doi":"10.36519/kd.2021.3574","DOIUrl":"https://doi.org/10.36519/kd.2021.3574","url":null,"abstract":"","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42497014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the Methods Used in the Diagnosis of Brucellosis","authors":"B. Uysal, Necati Mumcu, Orhan Yıldız, B. Aygen","doi":"10.36519/kd.2021.3548","DOIUrl":"https://doi.org/10.36519/kd.2021.3548","url":null,"abstract":"Objective: The aim of the present study was to compare the new serological tests “immuncapture agglutination” (Bru- cellacapt, Vircell, Granada, Spain), enzyme-linked immunosorbent assay (ELISA) and the classical tests for diagnosis of acute, subacute or chronic brucellosis. Methods: Forty-nine samples of patients who presented with fever and clinical suspicion of brucellosis and who were admitted to Infectious Disease Department of Erciyes University Hospital with agglutination (SAT) titers ≥1/10 were collected during 2010 and 2012. And 30 healthy volunteers were enrolled in the study. All samples were subjected to the Brucella spp. Spesific culture, STA test, Brucellacapt test and ELISA for detection of IgM, IgA, and IgG. Coombs test was performed for 28 samples with titers <1/160 as measured by STA. Cohen’s kappa test was used to evaluate the correlation between the tests. Results: Blood culture was positive in 6 (12, 2%), joint fluid culture in 2 (4%), STA test in 21 (42, 8%), Brucellacapt test in 36 (73.4%), ELISA IgG in 33 (67.3%), ELISA IgM in 33 (67.3%), ELISA IgA in 31 (61.2%) of 49 patients. While STA, brucellacapt ve ELISA IgA tests were negative in all of the control group (n=30), in four individuals (%13.3) ELISA IgG, three individuals (%10) ELISA IgM were found low positive. When STA test was taken as the reference method, the sensitivities were found to be 100% in brucellacapt test, 85.7%, 90.4%, 90.% in ELISA IgG, IgM, IgA respectively and 23.8% in blood culture. Specifities were 74.1%, 67.2%, 67.2%, 79.3% and 98.2% respectively. When presence of clinical findings are taken as a reference, brucellacapt test was found to be most compatible (κ=0,66). Conclusions: STA was found to be unsatisfactory in the diagnosis of brucellosis in patients. Brucellacapt and/or ELISA tests are suggested to be used to verify results of STA.","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47896472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Utility and Prognostic Value of Basic Laboratory Parameters in COVID-19","authors":"Tülay Ünver-Ulusoy, Mesut Demirköse, H. Bilek","doi":"10.36519/kd.2021.3666","DOIUrl":"https://doi.org/10.36519/kd.2021.3666","url":null,"abstract":"Objective: Severe respiratory syndrome Coronavirus-2 (SARS-CoV-2) caused a global pandemic that spread all over Turkey following the announcement of the first case on March 11, 2020. The present study aimed to investigate the diagnostic utility of complete blood count (CBC) parameters, C-reactive protein (CRP), and their ratios as well as their prediction on intensive care unit (ICU) admission among patients with Coronavirus Disease-2019 (COVID-19).","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49323443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticle Liposomes: a New Strategy in Bacterial Infections","authors":"Perihan Erkan-Alkan, M. Güneş, C. Özakın, A. Sabancı","doi":"10.36519/KD.2021.3633","DOIUrl":"https://doi.org/10.36519/KD.2021.3633","url":null,"abstract":"Objective: In our study, a nanoparticle liposome molecule with patent application number TR201804452A2 was used, and the Minimum Inhibitor Concentration (MIC) was found to be 1562 ppm. According to the ASTM F 1980 standard, it has been determined that the nanoparticle liposome solution kept at 37 days and 55 oC in return for one-year stability preserves its effectiveness. Our study aimed to show that the newly developed solution maintains its effectiveness for a long time.\u0000\u0000Methods: CLSI M07-A10 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Tenth ed. Approved Standard) standard test method of the nanoparticle liposome solution developed with a technique different from the standard ozonation mechanisms, and antibacterial tests were performed by modifying the contact time and the MIC value of the solution, and its effect on time has been determined. For the stability test of the nanoparticle liposome solution, it was kept at 55 oC for 37 days in return for one-year stability according to the ASTM F 1980 standard.\u0000\u0000Results: MIC of nanoparticular ozone solution CLSI M07-A10 standard test method for S. aureus (ATCC 25923) and E. coli (ATCC 25922) strains by modifying contact time It was determined as 1.562 ppm. For S. aureus (ATCC 25923), at the end of the first hour, it was determined that the activity started at 2000 and 1750 ppm nanoparticle liposome solution concentration. For E. coli (ATCC 25922) it was determined that the activity started at the 10th minute at 2000 ppm nanoparticular ozone solution concentration. The solution was still effective at the end of one year according to the ASTM F 1980 standard in terms of effectiveness.\u0000\u0000Conclusions: As a result, the nanoparticle liposome solution, a new product, does not lose its stability and effectiveness for a long time, contrary to what is known. Although the half-life of gaseous ozone is as short as 20 minutes, the stability in the nanoparticle liposome solution has been determined as at least one year. Since nanoparticle liposome solution is a natural and slow-release product, it is thought that it can create a barrier in mucosal membranes in regions such as the nose, throat, eye and ear with solutions to be prepared in appropriate doses thus preventing bacteria from settling.\u0000\u0000Keywords: Nanoparticle liposomes, ozone, antibacterial efficiency, Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC 25922)","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43337619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Epstein-Barr Virus Antibodies by Chemiluminescent Microparticle Immunoassay Method in Patients of Different Age Groups: Evaluation of Atypical Serological Profiles","authors":"A. Duran, Tuğba Kula Ati","doi":"10.36519/KD.2021.3511","DOIUrl":"https://doi.org/10.36519/KD.2021.3511","url":null,"abstract":"Objective: Epstein-Barr virus (EBV) can cause different clinical pictures from infectious mononucleosis (IM) to malignancies such as B-cell lymphomas, Burkitt’s lymphoma, nasopharyngeal carcinoma, and Hodgkin lymphoma. VCA-IgM, VCA-IgG, EBNA-1 IgG antibodies are the most commonly used antibodies in revealing the serological profile. This study aimed to examine the serological profiles of patients with suspected EBV infection and to interpret the atypical profiles encountered.\u0000\u0000Methods: The results of VCA-IgM, VCA-IgG, and EBNA-1 IgG antibodies studied in the Microbiology Laboratory between 2017-2019 were evaluated retrospectively. EBV serological tests (VCA-IgM, VCA-IgG, and EBNA-1 IgG) were performed according to the manufacturer’s recommendations using the chemiluminescent microparticle immunoassay (CMIA) method (Architect, Abbott, Wiesbaden, Germany).\u0000\u0000Results: Of the 2486 patients evaluated, 1341 (53.9%) were male, 1145 (46.1%) were female, and the average age was determined as 16.93 ± 19.5. EBV past infection was detected in 56.65% of the cases, the acute infection was detected in 17.25%, and 21.09% did not encounter EBV. Atypical serological profile was detected in 5.01%. As an atypical profile, the most common positivity of three antibodies together (3.90%), then isolated VCA-IgG positivity (0.91%), and isolated EBNA-1 IgG positivity (0.20%) were determined. It was determined that 24.24% of the cases with an atypical profile were immunosuppressive patient. \u0000\u0000Conclusions: The rate of encountering EBV in our study is 78.91%. The atypical EBV serological profile rate was found to be 5.01%. Approximately one-fourth of the cases with an atypical profile was found to be in the patient group with immune disorders. It is thought that antibody tests are not sufficient to determine the stage of infection, especially in these patient groups, and further tests should be performed. It has been demonstrated that serological monitoring is required for the interpretation of atypical profiles.\u0000\u0000Keywords: Epstein-Barr virüs, serological tests, chemiluminescent microparticle immunoassay (CMIA), atypical serological profile","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45831511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the Frequency of Adverse Effects in Patients Treated with Favipiravir as SARS-CoV-2 Treatment","authors":"Ebru Dogan, Sevil Alkan-Çeviker, Servan Vurucu, A. Şener, Buse Yüksel, Uğur Gönlügür, T. Şimşek, Mehmet Hakan Ulusoy","doi":"10.36519/KD.2021.3563","DOIUrl":"https://doi.org/10.36519/KD.2021.3563","url":null,"abstract":"Objective: For 2019 and 2020, SARS-CoV-2 has been a sensational virus. Unfortunately, a treatment agent specific for SARS-CoV-2 has not been developed yet. Favipiravir is one of the antiviral agents used experimentally in the treatment of SARS-CoV-2. This study aimed to determine the frequency of side effects seen in patients hospitalized in our hospital and received favipiravir at any stage of their treatment.\u0000\u0000Methods: Our study is a retrospective observational study. Definite and probable COVID-19 cases hospitalized in our hospital between March 23, 2020, May 31, 2020, were determined, and those receiving favipiravir as initial or secondary therapy were included in the study. The demographic data, laboratory tests, observed side effects of the patients were recorded and analyzed statistically.\u0000\u0000Results: A total of 134 patients, 37.3% using favipiravir at the beginning and 62.7% as secondary, were included in the study. The mean age of the patients was 66.8±15.7 years. 38.1% (n=51) of the group were female. Side effects were detected in 17 (13%) patients in the whole group. Hepatotoxicity (4.5%), increased serum uric acid (4.5%), nephrotoxicity (1.5%), gastrointestinal side effects (1.5%), cardiac side effects (0.7%) were detected. There was no statistically significant difference in terms of adverse events between the patients who received favipiravir initially or later on disease course.\u0000\u0000Conclusions: Although some results support the short-term safety of favipiravir, more studies are needed for its long-term effects. Studies on hyperuricemia, QTc prolongation, use in pregnancy, use during lactation and use in children are insufficient. Therefore, although Favipiravir appears to be a good alternative in the treatment of COVID-19, it should be used carefully because the data on its safety is still insufficient.\u0000\u0000Key Words: Favipiravir, adverse effects, COVID-19, SARS-CoV-2","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42795786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Tonsillar Tuberculosis: A Case Report","authors":"Sinem Dasli, Hasan Naz, A. Eruyar, Canan Naz, Sebla Çalışkan","doi":"10.36519/KD.2021.14","DOIUrl":"https://doi.org/10.36519/KD.2021.14","url":null,"abstract":"Tuberculosis still maintains its place among important diseases today. This is becoming a problem not only in developing countries but also in developed countries. Upper respiratory tuberculosis is rare in our country. Tuberculosis bacillus can settle in the mouth, tonsils, tongue, nose, epiglottis, larynx, and pharynx. A 16-year-old female patient living in a dormitory was admitted to our clinic with the complaint of tonsillitis recurring 8-9 times a year and a chronic sore throat. Tonsillectomy operation was performed, and tonsillar tissues were sent for pathological examination. Pathology result was reported as caseified granulomatous tonsillitis. Her tuberculin skin test was 20 mm in diameter. The Ziehl-Neelsen staining examination of tonsillar tissue revealed tuberculosis bacillus stained positively in two areas. Other respiratory organs examined for tuberculosis and was found to be normal. With the diagnosis of primary tonsil tuberculosis, the patient was started on anti-tuberculosis treatment with isoniazid, rifampicin, ethambutol, and pyrazinamide. After two months of quadruple therapy, isoniazid and rifampicin were given for additional 4 months. The patient is now in the second year after the treatment and no recurrence finding has been observed. Tuberculosis is a disease that can affect all organs and tissues. In this respect, in case of suspicion pathological and microbiological examination of postoperative tonsillectomy materials is particularly important.","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69624864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic Resistance in Pseudomonas aeruginosaIsolated from Hospital and Community-Acquired Infections: Current Status in Northern Cyprus","authors":"B. Baddal, E. Güler, Kaya Süer","doi":"10.36519/KD.2021.06","DOIUrl":"https://doi.org/10.36519/KD.2021.06","url":null,"abstract":"Objective: Pseudomonas aeruginosa is among the most common nosocomial opportunistic pathogens capable of acquiring multi-drug resistance. Recent data on antibiotic resistance in Northern Cyprus is limited. We aimed evaluate antibiotic susceptibility profiles of P. aeruginosa strains isolated from clinical samples and contribute to the update of antibiotic use policies in the country. Methods: Total of 504 P. aeruginosa strains sent to Microbiology Laboratory from various clinics from September 2016 to October 2019 were retrospectively analyzed. Clinical samples were cultured on %5 sheep blood agar and eosin-methylene blue agar. BD Phoenix™ 100 (Becton Dickinson Co., Sparks, Maryland, USA) automated bacterial identification system and conventional antimicrobial susceptibility testing was used. Antimicrobial susceptibility was determined in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. The distribution of P. aeruginosa isolates according to hospital services, sample types, admission types, age group, and antibiotic resistance rates were investigated. Results: P. aeruginosa was mostly isolated from urine (37.3%), deep tracheal aspirate (17.9%) and abscess/wound material (17.9%) samples. Strains were most commonly obtained from the intensive care clinics (35.9%). Infections were observed mainly in >65 age group (49.6%) and in-patients (70.8%) group. Antibiotic resistance rates were detected as 47.7% for aztreonam, 32% for cefepime, 26.3% for ceftazidime, 26.4% for imipenem, 25.6% for ciprofloxacin, 24.6% for meropenem, 19.7% for piperacillin-tazobactam, 13.5% for gentamicin, 12.2% for colistin and 5.3% for amikacin. Multi-drug resistant P. aeruginosa rate was 19.2%. When compared with 2010-2014, a substantial increase in rates of cefepime, ceftazidime, ciprofloxacin, piperacillin-tazobactam and carbapenem resistance was detected within the last three years. Conclusions: In this study, the highest resistance rates were detected against aztreonam and cefepime, and the highest susceptibility was observed for colistin and amikacin. These results may be used for empirical treatments, establishment of rational antibiotic use policies and prevention of emerging antibiotic resistance problem in Cyprus.","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69624813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}